Eisai GAAP EPS of ¥160.14, revenue of ¥601.16B; reaffirms FY outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 07 2025
0mins
Source: SeekingAlpha
Earnings Report: Eisai reported a GAAP EPS of ¥160.14 and revenue of ¥601.16 billion for the nine-month period ending December 31, 2024, reflecting a year-over-year increase of 9.1%.
Drug Development Updates: The review of Eisai and Biogen's Alzheimer's drug has been delayed in the EU, while mixed Phase 3 data was reported for their Keytruda/Lenvima combination in gastrointestinal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
